UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis

Journal of allergy and clinical immunology, 2014-12, Vol.134 (6), p.1293-1300

2014

Volltextzugriff (PDF)

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

The New England journal of medicine, 2014-07, Vol.371 (2), p.130-139

2014

Volltextzugriff (PDF)

Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)

Annals of the rheumatic diseases, 2015-06, Vol.74 (6), p.1051-1057

2015

Volltextzugriff (PDF)

Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases

Clinical and experimental allergy, 2021-07, Vol.51 (7), p.915-931

2021

Volltextzugriff (PDF)

Passive Prophylactic Administration with a Single Dose of Anti–Fel d 1 Monoclonal Antibodies REGN1908–1909 in Cat Allergen–induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial

American journal of respiratory and critical care medicine, 2021-07, Vol.204 (1), p.23-33

2021

Volltextzugriff (PDF)

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

Annals of the rheumatic diseases, 2014-09, Vol.73 (9), p.1626-1634

2014

Volltextzugriff (PDF)

Pharmacokinetics and Concentration‐Response of Dupilumab in Patients With Seasonal Allergic Rhinitis

Journal of clinical pharmacology, 2022-05, Vol.62 (5), p.689-695

2022

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects

Clinical pharmacology in drug development, 2020-08, Vol.9 (6), p.742-755

2020

Volltextzugriff (PDF)

REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics

Clinical and translational science, 2021-11, Vol.14 (6), p.2440-2449

2021

Volltextzugriff (PDF)

First-in-Human Study of REGN668/SAR231893 (IL-4Rα mAb): Safety, Tolerability and Biomarker Results of a Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Volunteers

Journal of allergy and clinical immunology, 2013-02, Vol.131 (2), p.AB158-AB158

2013

Volltextzugriff (PDF)

Dupilumab Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study

Journal of allergy and clinical immunology, 2014-02, Vol.133 (2), p.AB404-AB404

2014

Volltextzugriff (PDF)

Rilonacept-CAPS and Beyond

Annals of the New York Academy of Sciences, 2009-12, Vol.1182 (1), p.124-134

2009

Volltextzugriff (PDF)

Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2016-02, Vol.315 (5), p.469

2016

Volltextzugriff (PDF)

Dupilumab in Persistent Asthma with Elevated Eosinophil Levels

The New England journal of medicine, 2013-06, Vol.368 (26), p.2455-2466

2013

Volltextzugriff (PDF)

Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis

Gastroenterology (New York, N.Y. 1943), 2020-01, Vol.158 (1), p.111-122.e10

2020

Volltextzugriff (PDF)

S212 A Phase 2 Study Design to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Adults With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S159-S160

2023

Volltextzugriff (PDF)

42011 Dupilumab Improves Urticaria Signs and Symptoms and Quality of Life in Patients With Chronic Spontaneous Urticaria (CSU)

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB40-AB40

2023

Volltextzugriff (PDF)

Dupilumab Improves Urticaria Activity And Quality Of Life In Patients With Chronic Spontaneous Urticaria (CSU)

Journal of allergy and clinical immunology, 2023-02, Vol.151 (2), p.AB98-AB98

2023

Volltextzugriff (PDF)

Efficacy of Anti-Allergen Therapeutics in Preclinical Allergy Model Systems Correlate with Symptomatic Relief in a Clinical Setting

Journal of allergy and clinical immunology, 2022-02, Vol.149 (2), p.AB162-AB162

2022

Volltextzugriff (PDF)

Dupilumab Significantly Reduces Itch and Hives in Patients With Chronic Spontaneous Urticaria: Results From a Phase 3 Trial (LIBERTY-CSU CUPID Study A)

Journal of allergy and clinical immunology, 2022-02, Vol.149 (2), p.AB312-AB312

2022

Volltextzugriff (PDF)

Clinical and immunological evaluation of cat-allergic asthmatics living with or without a cat

The Journal of immunology (1950), 2020-05, Vol.204 (1_Supplement), p.65-65.25

2020

Volltextzugriff (PDF)

Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

Journal of allergy and clinical immunology, 2024-07, Vol.154 (1), p.184-194

2024

Volltextzugriff (PDF)

Rilonacept—CAPS and Beyond: A Scientific Journey

Annals of the New York Academy of Sciences, 2009-01, Vol.1182 (1), p.124-134

2009

Volltextzugriff (PDF)

Clinical and immunological evaluation of cat‐allergic asthmatics living with or without a cat

Clinical and experimental allergy, 2021-12, Vol.51 (12), p.1624-1633

2021

Volltextzugriff (PDF)

Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E Levels

Dermatology and therapy, 2024-07

2024

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(50)

Publikationsform

Sprache

Englisch
(58)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)

Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases

Passive Prophylactic Administration with a Single Dose of Anti–Fel d 1 Monoclonal Antibodies REGN1908–1909 in Cat Allergen–induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

Pharmacokinetics and Concentration‐Response of Dupilumab in Patients With Seasonal Allergic Rhinitis

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects

REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics

First-in-Human Study of REGN668/SAR231893 (IL-4Rα mAb): Safety, Tolerability and Biomarker Results of a Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Volunteers

Dupilumab Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study

Rilonacept-CAPS and Beyond

Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial

Dupilumab in Persistent Asthma with Elevated Eosinophil Levels

Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis

S212 A Phase 2 Study Design to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Adults With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype

42011 Dupilumab Improves Urticaria Signs and Symptoms and Quality of Life in Patients With Chronic Spontaneous Urticaria (CSU)

Dupilumab Improves Urticaria Activity And Quality Of Life In Patients With Chronic Spontaneous Urticaria (CSU)

Efficacy of Anti-Allergen Therapeutics in Preclinical Allergy Model Systems Correlate with Symptomatic Relief in a Clinical Setting

Dupilumab Significantly Reduces Itch and Hives in Patients With Chronic Spontaneous Urticaria: Results From a Phase 3 Trial (LIBERTY-CSU CUPID Study A)

Clinical and immunological evaluation of cat-allergic asthmatics living with or without a cat

Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

Rilonacept—CAPS and Beyond: A Scientific Journey

Clinical and immunological evaluation of cat‐allergic asthmatics living with or without a cat

Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E Levels

Suchergebnisse filtern